Novartis CAAA61712301: An International Prospective, Open-Label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard or Care, versus Standard of Care Alone, in Adult Male Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
